GLTO
NASDAQ HealthcareGalecto, Inc. - Common Stock
Biotechnology
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
๐ Market Data
| Price | $25.36 |
|---|---|
| Volume | 226,680 |
| Market Cap | 1.73B |
| Beta | 1.570 |
| RSI (14-Day) | 43.5 |
| 200-Day MA | $17.12 |
| 50-Day MA | $26.16 |
| 52-Week High | $38.33 |
| 52-Week Low | $2.01 |
| Forward P/E | -30.20 |
| Price / Book | 5.71 |
๐ฏ Investment Strategy Scores
GLTO scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (88/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (12/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find GLTO in your text
Paste any article, transcript, or post โ the tool will extract GLTO and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.